About Zinc finger protein PLAGL1
Zinc finger protein PLAGL1 (PLAGL1) is a protein
from Homo sapiens identified by UniProt accession
Q9UM63, 463 residues long.
MolForge cross-references it against 0 known binders and
167 disease associations.
Target properties
| Protein name | Zinc finger protein PLAGL1 |
| UniProt accession | Q9UM63 |
| Gene | PLAGL1 |
| Organism | Homo sapiens |
| Length | 463 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (167)
Diseases linked to this target (Open Targets).
- testosterone measurement · score 0.48
- monocyte count · score 0.46
- monocyte percentage of leukocytes · score 0.43
- eosinophil count · score 0.42
- lymphocyte percentage of leukocytes · score 0.37
- neutrophil percentage of leukocytes · score 0.37
- transient neonatal diabetes mellitus · score 0.37
- neurodegenerative disease · score 0.35
- resistin measurement · score 0.34
- body mass index · score 0.31
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UM63-F1 | alphafold | PREDICTED | 56.59 | — |
Amino-acid sequence (463 residues)
MATFPCQLCG KTFLTLEKFT IHNYSHSRER PYKCVQPDCG KAFVSRYKLM RHMATHSPQK SHQCAHCEKT FNRKDHLKNH LQTHDPNKMA FGCEECGKKY NTMLGYKRHL ALHAASSGDL TCGVCALELG STEVLLDHLK AHAEEKPPSG TKEKKHQCDH CERCFYTRKD VRRHLVVHTG CKDFLCQFCA QRFGRKDHLT RHTKKTHSQE LMKESLQTGD LLSTFHTISP SFQLKAAALP PFPLGASAQN GLASSLPAEV HSLTLSPPEQ AAQPMQPLPE SLASLHPSVS PGSPPPPLPN HKYNTTSTSY SPLASLPLKA DTKGFCNISL FEDLPLQEPQ SPQKLNPGFD LAKGNAGKVN LPKELPADAV NLTIPASLDL SPLLGFWQLP PPATQNTFGN STLALGPGES LPHRLSCLGQ QQQEPPLAMG TVSLGQLPLP PIPHVFSAGT GSAILPHFHH AFR
Explore Zinc finger protein PLAGL1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets